Author

C. Wickenhauser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:scRNA-seq· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Trumpp· 2 shared C. Mueller-Tidow· 2 shared M. Bauer· 2 shared M. Hundemer· 2 shared S. Haas· 2 shared A. Jauch· 1 shared A. K. Ludwig· 1 shared A. Schott· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Trumpp

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapy

R. Lutz, F. Gruenschlaeger, M. Simon, M. Bauer, S. Yousefian, N. Beumer, L. Jopp-Saile, M. Awwad, G. Steinbuss, A. Sedlmeier, T. Boch, D. Vonficht, M.-A. Baertsch, B. Durie, N. Weinhold, , S. Haas

This study examines immune changes in multiple myeloma survivors years after treatment, finding sustained immune alterations linked to residual disease and therapy.

bioRxiv · May 27, 2023 · PreprintCancer Biology

Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia

S. Beneyto-Calabuig, A. K. Ludwig, J.-A. Kniffka, C. Szu-Tu, C. Rohde, M. Antes, A. Waclawiczek, P. Pervan, M. Janssen, J. J. M. Landry, V. Benes, A. Jauch, M. Brough, M. Bauer, B. Besenbeck, , L. Velten

CloneTracer identifies differentiation routes in AML by adding clonal resolution to single-cell RNA-seq data, revealing disease-defining compartments and therapy response mechanisms.

bioRxiv · Aug 29, 2022Cancer Biology

IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer

N. Bley, A. Schott, S. Mueller, D. Misiak, M. Lederer, T. Fuchs, C. Assmann, M. Glass, C. Ihling, A. Sinz, N. Pazaitis, C. Wickenhauser, M. Vetter, O. Ungurs, H.-G. Strauss, , S. Huettelmaier

This study identifies IGF2BP1 as a driver of invasive growth in ovarian cancer through SRC/MAPK signaling, showing that combinatorial SRC/MEK inhibition is effective in treating mesenchymal-like HG-SOC.

bioRxiv · Jun 19, 2020Cancer Biology